TD Cowen Stands by Buy Rating for Tenet Healthcare
TD Cowen reaffirms its buy rating on Tenet Healthcare with a $233 price target, a 26.54% upside from the current price.
Key Points
- On June 22, 2026, TD Cowen reiterated its buy rating on Tenet Healthcare with a price target of $233.
- TD Cowen's $233 price target implies 26.54% upside from Tenet Healthcare Corporation's ($THC) current $184.13 share price.
- Tenet Healthcare, trading at $177.56 on Monday, has a market cap of $14.86 billion and a P/E ratio of 8.98.
- Recent insider activity includes sales by Robert Kerrey and buys by several others, while analysts maintain strong buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, TD Cowen reiterated its buy rating on Tenet Healthcare Corporation (NYSE:THC), setting a price target of $233. Analyst Ryan Langston remains positive on the stock, which traded at $177.56 on Monday.
TD Cowen vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Tenet Healthcare Corporation Stock Down 31.0%
Shares of NYSE:THC traded near $177.56 on Monday. Tenet Healthcare has a market cap of about $14.86 billion, with a P/E ratio of 8.98 and a forward P/E of 9.74. The stock has a 52-week low of $146.60 and a high of $247.21, with a 50-day moving average of $182.92 and a 200-day moving average of $198.78. Its beta is 1.28, indicating more volatility compared to the broader market.
$THC price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its most recent earnings report, Tenet Healthcare posted revenue of approximately $21.45 billion, reflecting a growth rate of 2.8%. The company's net margin stood at 7.94%, and its return on equity was 30.29%. The next earnings release is anticipated on July 21, 2026.
Insider Buying and Selling at Tenet Healthcare Corporation
Insider activity at Tenet Healthcare saw Robert Kerrey selling 5,638 shares on May 28, 2026, at an average price of $174.52. On the buying side, Richard Fisher, Cecil Haney, James Bierman, Tammy Romo, and Richard Mark each acquired 1,188 shares on May 27, 2026.
Analysts Set New Price Targets
TD Cowen maintained its buy rating on June 22, 2026, with a target price of $233. Previously, on May 5, 2026, Barclays also maintained a buy rating with a $238 target, while Baird held a hold rating with a $210 target. Stephens & Co. set a buy rating with a $260 target on May 4, 2026. The consensus rating for Tenet Healthcare is a strong buy, with a mean target price of $243.62 from 21 analyst opinions.
About Tenet Healthcare Corporation
Tenet Healthcare Corporation is a major player in the healthcare sector, operating diversified healthcare services across the United States. Based in Dallas, Texas, and led by CEO Dr. Saumya Sutaria, the company runs general hospitals, ambulatory care centers, and specialty hospitals. Founded in 1967, Tenet employs around 77,000 people and offers a wide range of medical services, including acute care, outpatient services, and specialized procedures.
Bottom Line
TD Cowen's reaffirmation of its buy rating with a $233 target highlights continued confidence in Tenet Healthcare's potential. Investors closely watch these ratings as indicators of market sentiment, although it's important to remember that analyst opinions are just one piece of the puzzle. As always, 13F filings and analyst ratings are backward-looking and may not reflect current conditions.
Get Tenet Healthcare Corporation alerts
New 13F filings, insider trades, and analyst moves on $THC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.